Status:
TERMINATED
Treatment of West Nile Virus With MGAWN1
Lead Sponsor:
MacroGenics
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
West Nile Neuroinvasive Disease
West Nile Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will test a drug called MGAWN1 for the treatment of West Nile infections.
Detailed Description
The objective of this study is to evaluate the safety, efficacy, and pharmacokinetics of MGAWN1 in subjects with West Nile Fever or a syndrome compatible with West Nile Neuroinvasive Disease (WNND) \[...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Provide written informed consent
- Be \>=18 years of age at the time of enrollment
- Have West Nile Fever defined as:
- temperature \>38°C, headache, AND
- positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF)
- OR have West Nile Neuroinvasive Disease (includes neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis), defined as:
- • West Nile encephalitis (must meet criteria a and b below)
- Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours)
- CSF pleocytosis \>=5 cells/mm\^3
- AND/OR
- • West Nile meningitis (must meet criteria c and d)
- Clinical signs of meningeal inflammation, including nuchal rigidity, Kernig or Brudzinski sign, photophobia, or phonophobia
- CSF pleocytosis \>=5 cells/mm\^3
- AND/OR
- • Acute flaccid paralysis (must meet criteria e and f)
- Acute onset of limb weakness with marked progression over 48 hours
- Two or more of the following conditions:
- asymmetry to weakness
- areflexia or hyporeflexia of affected limb(s)
- absence of pain, paresthesia, or numbness in affected limb(s)
- CSF pleocytosis \>=5 cells/mm\^3
- CSF elevated protein levels (4.5 g/L)
- electrodiagnostic studies consistent with an anterior horn cell process
- or abnormal increased signal in the anterior gray matter as documented by spinal cord magnetic resonance imaging
- Have epidemiological factors consistent with West Nile Virus infection (must meet criterion a or b below):
- Appropriate time of year for West Nile Virus transmission in region
- Travel history to a region where West Nile Virus is active
- Develop signs and/or symptoms within 14 days before study enrollment.
- If female of childbearing potential or male and in a sexual relationship with a female of childbearing potential, agree (or have partner agree) to practice abstinence or use 2 of the following methods of contraception for 120 days (approximately 4 months) after study drug administration:
- Oral contraceptives, or other form of hormonal birth control including hormonal vaginal rings or transdermal patches
- An intrauterine device
- Barrier contraception (condom) with a spermicide (i.e., female subject ensures use by male partner\[s\])
- Any other equivalent method of contraception (as judged by the investigator)
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00927953
Start Date
May 1 2009
End Date
May 1 2011
Last Update
February 10 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.